TEVA-HANDOK received permission for bioequivalence test of 'Aricept' for the first time in Korea
TEVA-HANDOK received permission for bioequivalence test to develop generic version of Aricept for the first time in Korea. Starting with this product, generic introduction is expected to be greatly expanded. Ministry of Food and Drug Safety authorized bioequivalence test of TEVA-H...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
